CKPT Share Price | Checkpoint Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Checkpoint Therapeutics, Inc. do?

Overview:Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company focused on the development and commercialization of immune-enhanced combination treatments for solid tumor cancers, operating within the Pharmaceuticals: Major industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)Market cap: USD 370.71 Million (Micro Cap)Key Metrics:Dividend Yield: 23.88%Debt Equity: -2.03Return on Equity: -345.95%Price to Book: 22.75Contact Details:Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667Tel: 1 212 5544366Website: http://www.checkpointtx.com

Q: Is Checkpoint Therapeutics, Inc. overvalued or undervalued?

As of 6 May 2021, the valuation grade for Checkpoint Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its high Price to Book Value of 22.75, an EV to Sales ratio of 337.66, and a negative ROE of -345.95%. In comparison, Journey Medical Corp. has a P/E of -18.6994 and Fortress Biotech, Inc. has a P/E of -1.1589, both indicating that Checkpoint is not competitively positioned within its peer group.Despite the overvaluation, Checkpoint Therapeutics has shown strong short-term performance, with a year-to-date return of 33.12%, significantly outperforming the S&P 500's 12.22%. However, the long-term outlook remains concerning, as the company has experienced a staggering -79.91% return over the past five years compared to the S&P 500's 96.61%.

Q: Is Checkpoint Therapeutics, Inc. technically bullish or bearish?

As of 14 April 2025, the technical trend for Checkpoint Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, KST, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. In terms of performance, the stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 33.12% compared to the S&P 500's 12.22%, and a one-year return of 132.79% versus 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

8.67 M

Shareholding (Mar 2025)

FII

7.13%

Held by 21 FIIs

DII

87.01%

Held by 10 DIIs

Promoter

0.00%

How big is Checkpoint Therapeutics, Inc.?

22-Jun-2025

As of May 29, Checkpoint Therapeutics, Inc. has a market capitalization of 370.71 million, with net sales of 0.04 million and a net profit of -56.50 million over the last four quarters. The balance sheet as of December 2024 shows shareholder's funds of -12.62 million and total assets of 7.47 million.

View full answer

What does Checkpoint Therapeutics, Inc. do?

22-Jun-2025

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company focused on developing immune-enhanced combination treatments for solid tumor cancers. It has a market cap of approximately $370.71 million and reported a net profit of -$11 million as of March 2025.

View full answer

Who are in the management team of Checkpoint Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Checkpoint Therapeutics, Inc. includes Chairman Michael Weiss, CEO James Oliviero, and several independent directors: Dr. Lindsay Rosenwald, Christian Bechon, Scott Boilen, Neil Herskowitz, and Barry Salzman. They oversee the company's strategic direction and operations.

View full answer

Is Checkpoint Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of May 6, 2021, Checkpoint Therapeutics, Inc. is considered overvalued with a valuation downgrade to "does not qualify," despite a strong year-to-date return of 33.12%, while its long-term performance shows a significant decline of -79.91% over five years compared to the S&P 500's 96.61%.

View full answer

Is Checkpoint Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of April 14, 2025, Checkpoint Therapeutics, Inc. has a bullish trend supported by strong technical indicators, outperforming the S&P 500 with a year-to-date return of 33.12% compared to 12.22% and a one-year return of 132.79% versus 17.14%.

View full answer

Compare Checkpoint Therapeutics, Inc. with Similar Stocks

Journey Medical Corp.Eledon Pharmaceuticals, Inc.CASI Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

USD 371 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

23.88%

Debt Equity

-2.03

Return on Equity

-345.95%

Price to Book

22.75

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

48.95%

6 Months

-2.96%

1 Year

132.79%

2 Years

58.36%

3 Years

-69.79%

4 Years

-84.1%

5 Years

-79.91%

Checkpoint Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-55.65%

EBIT Growth (5y)

-188.17%

EBIT to Interest (avg)

-49.14

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.03

Sales to Capital Employed (avg)

-0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

79.03%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

22.75

EV to EBIT

-5.99

EV to EBITDA

-5.99

EV to Capital Employed

-20.16

EV to Sales

337.66

PEG Ratio

Dividend Yield

23.88%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-345.95%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 6 Schemes (5.86%)

Foreign Institutions

Held by 21 Foreign Institutions (7.13%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 61.25% vs -197.94% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.10",
          "val2": "-28.80",
          "chgp": "61.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-28.90",
          "chgp": "61.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.49% vs 17.25% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-56.20",
          "val2": "-52.10",
          "chgp": "-7.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.20",
          "chgp": "-150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.20",
          "val2": "-51.80",
          "chgp": "-8.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,370,097.60%",
          "val2": "-506,291.30%",
          "chgp": "-86,380.63%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.10

-28.80

61.46%

Interest

0.00

Exceptional Items

-0.10

Consolidate Net Profit

-11.20

-28.90

61.25%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 61.25% vs -197.94% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

0.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-56.20

-52.10

-7.87%

Interest

0.00

Exceptional Items

-0.10

0.20

-150.00%

Consolidate Net Profit

-56.20

-51.80

-8.49%

Operating Profit Margin (Excl OI)

-1,370,097.60%

-506,291.30%

-86,380.63%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.49% vs 17.25% in Dec 2023

All Annual Results

Company CV

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc.

Pharmaceuticals: Major

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

Company Coordinates

Company Details

2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667

Tel: 1 212 5544366

http://www.checkpointtx.com

Registrar Details

Checkpoint Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Checkpoint Therapeutics, Inc.?

Watch in Real-Time

What does Checkpoint Therapeutics, Inc. do?

Who are in the management team of Checkpoint Therapeutics, Inc.?

Is Checkpoint Therapeutics, Inc. overvalued or undervalued?

Is Checkpoint Therapeutics, Inc. technically bullish or bearish?

Compare Checkpoint Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Checkpoint Therapeutics, Inc.

Company Coordinates